The Real Cost Isn't the Analysis.
It's the Wrong Decision.

MTV, TLG, viable tumor volume. Quantitative endpoints that turn trial signals into defensible go/no-go decisions.

Discuss Your Endpoints

See It Live

FDA 21 CFR Part 11 HIPAA GDPR PIPEDA AWS

How it works

From DICOM to Decision. Four Steps.

Step 01

Define Your Endpoints

Define endpoints with our medical team: MTV, viable tumor volume, TLG, or custom biomarkers.

Radiology

Step 02

Collect via BioSUITE

Imaging data flows through BioSUITE with automated QA. No separate transfers or handoffs.

Automated QA/QC

Step 03

Analyze with Precision

Oncology subspecialists perform volumetric analysis: ROI transfer, quantitative measurements across timepoints.

Subspecialist readers

Step 04

Decide with Data

Results delivered in BioSUITE dashboard. Interactive visualizations, 3D renderings, raw data export.

Interactive dashboard

What We Measure

Beyond RECIST. Beyond Guessing.

Endpoints for regulatory submissions, go/no-go calls, and partner presentations.

Volumetric Endpoints

Total Metabolic Tumor Volume (MTV)

PET/CT

Mandatory for lymphoma (LUGANO) and prostate (RECIP 1.0). Quantifies active disease burden.

Viable Tumor Volume

MRI

Critical for GBM (RANO 2.0). Differentiates active tumor from necrosis.

Total Lesional Glycolysis (TLG)

PET/CT

Metabolic volume × intensity. Stronger predictor than SUVmax alone.

ΔVolume Trending

All

Diameter lags. Volume leads — revealing true tumor dynamics when it still matters.

Functional & Structural Biomarkers

Tumor vascularity and perfusion changes

Tracking CT electronic density and MRI cellular density to capture treatment-driven microscopic changes

Peritumoral edema and surrounding morphology shifts

Fibrosis, calcification, hemorrhage detection (macroscopic changes)

Custom biomarker development

Modality Coverage

PET/CT MRI CT SPECT Whole-body

When to Use Advanced Analysis

The Right Analysis for Every Decision.

Your Situation

Where you are now

What You Need

The gap to close

What We Deliver

Volumetryx solution

1Early phase mixed signal — board wants go/no-go

Defensible state-of-the-art quantitative evidence

✓MTV + volume trending + statistical analysis in interactive dashboard

2Investor/partner presentation preparation

Biological depth beyond RECIST/Lugano response buckets

✓3D renderings, exportable volumetric data, presentation-ready analytics

3Designing next-phase protocol

Data-driven inclusion, arm stratification, endpoints

✓Turn prior and ongoing imaging into actionable evidence

4Regulatory submission preparation

FDA-accepted surrogate endpoints with proper documentation

✓Volumetric endpoints formatted for FDA submission packages

5Post-trial exploratory analysis

Maximize value from data already collected

✓Re-analysis of existing DICOMs with new volumetric endpoints

Why Volumetryx

Not an Add-On. A Core Service.

Core Service, Not an Add-On

Fast setup, dedicated analysis team, defined turnaround. Not outsourced to a third lab six weeks into your trial.

Core service

Integrated with BioSUITE

Images in BioSUITE flow directly into analysis. No handoffs, no extra contracts.

Integrated

Full Raw Data Access

Export raw measurements, segmentation files, ROI data. Verify with your own team.

Open data

Interactive Dashboard Delivery

Interactive visualizations, patient-level drill-down, exportable charts. Not a PDF in an inbox.

Interactive

Oncology Subspecialist Team

Subspecialty-trained readers. Not generalists reading everything.

Subspecialist

Decision-Framework Oriented

Every measurement framed for your go/no-go. Context, not just numbers.

Decision-ready

The Real Cost Isn't the Analysis. It's the Wrong Decision.